期刊
GENES
卷 12, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/genes12060920
关键词
small-molecule inhibitors; DNA repair; homologous recombination; triple-negative breast cancer
资金
- NCI: National Institutes of Health [R01 CA188347, P30CA056036]
- NIH/NIAID [R01AI150491]
By using a medicinal chemistry approach, the potency of B02 in inhibiting HR was improved and a B02 analog, B02-isomer, was discovered to synergize with PARPi in triple-negative breast cancer cells.
Targeting DNA repair proteins with small-molecule inhibitors became a proven anti-cancer strategy. Previously, we identified an inhibitor of a major protein of homologous recombination (HR) RAD51, named B02. B02 inhibited HR in human cells and sensitized them to chemotherapeutic drugs in vitro and in vivo. Here, using a medicinal chemistry approach, we aimed to improve the potency of B02. We identified the B02 analog, B02-isomer, which inhibits HR in human cells with significantly higher efficiency. We also show that B02-iso sensitizes triple-negative breast cancer MDA-MB-231 cells to the PARP inhibitor (PARPi) olaparib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据